Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $286.49, for a total transaction of $2,864,900.00. Following the transaction, the chief executive officer now directly owns 475,042 shares in the company, valued at approximately $136,094,783. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on ICPT shares. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday, August 15th. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday, August 14th. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday, August 12th. They now have a $456.00 price target on the stock, up previously from $323.00. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $472.91.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.55% on Thursday, hitting $286.70. The stock had a trading volume of 292,864 shares. Intercept Pharmaceuticals has a 52 week low of $45.55 and a 52 week high of $497.00. The stock has a 50-day moving average of $257.1 and a 200-day moving average of $288.1. The company’s market cap is $6.083 billion. Intercept Pharmaceuticals also was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 595,961 shares, a drop of 25.1% from the July 31st total of 795,445 shares. Currently, 4.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,067,623 shares, the short-interest ratio is presently 0.6 days.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.34 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.